Inclusion Criteria:

          -  Patient had a confirmed diagnosis of a select solid tumor (except ALK+ NSCLC) or
             hematological malignancy and was in need of treatment because of radiologic
             progression or relapse.

          -  Patient must have been pre-identified as having a tumor with an ALK or ROS1 positive
             mutation, translocation, rearrangement or amplification. The qualifying alteration
             must have been assessed and reported by a CLIA-certified laboratory. ALK positivity as
             assessed by IHC or FISH were allowed.

          -  Patient must have received at least one prior treatment for recurrent, metastatic
             and/or locally advanced disease and for whom no standard therapy options were
             anticipated to result in a durable remission.

          -  Patient had progressive and measurable disease as per RECIST 1.1 or other appropriate
             hematological guidelines.

          -  Patient had an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.

        Exclusion Criteria:

          -  Patient had received prior treatment with ceritinib.

          -  Patients with symptomatic CNS metastases who were neurologically unstable or required
             increasing doses of steroids within the 2 weeks prior to study entry to manage CNS
             symptoms.

          -  Patient had received chemotherapy or anticancer therapy ≤ 4 weeks (6 weeks for
             nitrosourea, monoclonal antibodies or mitomycin-C) prior to starting study drug.